Amber L Zeeman
Overview
Explore the profile of Amber L Zeeman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jeremiasse B, van Ineveld R, Bok V, Kleinnijenhuis M, de Blank S, Alieva M, et al.
EMBO Mol Med
. 2024 Jun;
16(7):1495-1514.
PMID: 38831131
Achieving complete tumor resection is challenging and can be improved by real-time fluorescence-guided surgery with molecular-targeted probes. However, pre-clinical identification and validation of probes presents a lengthy process that is...
2.
Alieva M, Barrera Roman M, de Blank S, Petcu D, Zeeman A, Dautzenberg N, et al.
Nat Protoc
. 2024 Mar;
19(7):2052-2084.
PMID: 38504137
Modeling immuno-oncology by using patient-derived material and immune cell co-cultures can advance our understanding of immune cell tumor targeting in a patient-specific manner, offering leads to improve cellular immunotherapy. However,...
3.
Vennin C, Cattaneo C, Bosch L, Vegna S, Ma X, Damstra H, et al.
Cancer Cell
. 2023 Jun;
41(6):1170-1185.e12.
PMID: 37311414
Although treatment with taxanes does not always lead to clinical benefit, all patients are at risk of their detrimental side effects such as peripheral neuropathy. Understanding the in vivo mode...
4.
Dekkers J, Alieva M, Cleven A, Keramati F, Wezenaar A, van Vliet E, et al.
Nat Biotechnol
. 2022 Jul;
41(1):60-69.
PMID: 35879361
Extending the success of cellular immunotherapies against blood cancers to the realm of solid tumors will require improved in vitro models that reveal therapeutic modes of action at the molecular...
5.
Boelens M, Nethe M, Klarenbeek S, de Ruiter J, Schut E, Bonzanni N, et al.
Cell Rep
. 2016 Aug;
16(8):2087-2101.
PMID: 27524621
Invasive lobular carcinoma (ILC) is an aggressive breast cancer subtype with poor response to chemotherapy. Besides loss of E-cadherin, a hallmark of ILC, genetic inactivation of PTEN is frequently observed...
6.
Shehata M, van Amerongen R, Zeeman A, Giraddi R, Stingl J
Breast Cancer Res
. 2014 Jul;
16(4):411.
PMID: 25056669
Introduction: Lineage tracing using inducible genetic labeling has emerged to be a powerful method for interrogating the developmental fate of cells in intact tissues. A common induction mechanism is the...